BRD3 and acute myeloid leukemia: Another recently developed CRBN-based PROTAC dBET1 has also shown very potent activity in degrading BRD2, BRD3, and BRD4 proteins in association with a potent anti-tumor activity in various AML cell lines (Zhang et al., 2022).